The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...

Amgen Inc (NASDAQ:AMGN)., a leading biopharmaceutical company with a market capitalization of $155 billion, is at a pivotal juncture as it navigates the competitive landscape of innovative ...

We recently published a list of Jim Cramer Discussed 10 Stocks Leading the Dow Higher in 2025. In this article, we are going ...

Amgen Inc.’s disclosed that US regulators paused the study of an early-stage obesity drug, a lucrative market the company is trying to crack. The Thousand Oaks, California-based drugmaker didn ...

Shares of the company began plunging in November, but its overall strength should set the stock up for some serious potential ...

MariTide Phase 3 studies to begin in first half of year FDA places hold on AMG 513 obesity drug trial Amgen's Q4 earnings beat estimates, revenue up 11% Feb 4 (Reuters) - Amgen (AMGN.O), opens new ...

The sales of these drugs have eroded due to competitive pricing from biosimilar counterparts. However, Amgen proactively launched its own biosimilars, such as Rayos and Pennsaid, to retain its ...

Stay informed and make well-considered decisions with our Ratings Table. Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and ...

So what better way to make the time fly ... The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback ...